Evidence map›Paper›PMID 34741527›Full record

ReviewInternational journal of cancer2022

Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment.

Anna Y Berghuis, Johan F A Pijnenborg, Thomas J Boltje, Johanna M A Pijnenborg

Open access · hybridAbstract readReview
In one paragraph

Review in International journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Sialic acidOncoimmunology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Targeting the ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) as a potential therapeutic strategy to overcome anti-VEGF resistance in endometrial cancer.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anna Y BerghuisFaculty of Science, Radboud University, Nijmegen, The Netherlands.ORCID 0000-0002-1784-7828
Johan F A PijnenborgCluster for Molecular Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands.
Thomas J BoltjeCluster for Molecular Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands.
Johanna M A PijnenborgDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-6138-1236
Radboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gynecological cancers are in the top 10 of most common cancers in women. Survival and outcome are strongly related to the stage at diagnosis. Therefore, early diagnosis is essential in reducing morbidity and mortality. The high mortality rate of gynecological cancers can mainly be attributed to ovarian cancer (OC). OC is commonly diagnosed at an advanced stage due to a lack of proper screening tools allowing early detection. Endometrial cancer (EC) on the contrary, is mostly diagnosed at an early stage and has, in general, better outcomes. The incidence of nonendometrioid EC has increased in the last decade, displaying a shared tumor biology with OC and consequently significantly worse outcome. New approaches allowing detection of gynecological cancers in an early stage are therefore desired. Recent studies on cancer biology have shown the relevance of altered glycosylation in the occurrence and progression of cancer. The aberrant expression of sialic acid, a specific carbohydrate terminating glycoproteins and glycolipids on the cell-surface, is frequently correlated with malignancy. We aimed to determine the current understanding of sialic acid function in different gynecological cancers to identify the gaps in knowledge and its potential use for new diagnostic and therapeutic avenues. Therefore we performed a review on current literature focusing on studies where sialylation was linked to gynecological cancers. The identified studies showed elevated levels of sialic acid in serum, tissue and sialylated antigens in most patients with gynecological cancers, underlining its potential for diagnosis.

Indexed as

Animalsbeta-Galactoside alpha-2,3-SialyltransferaseCell Line, TumorDisease ProgressionFemaleGenital Neoplasms, FemaleGlycosylationHumansSialic AcidsSialyltransferasesbeta-Galactoside alpha-2,3-SialyltransferaseSialic AcidsSialyltransferasesST3GAL1 protein, humanbiomarkerdiagnosisgynecological cancerprognosissialic acid

Identifiers

PMID34741527
PMCPMC9299683
OpenAlexW3208073097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.